16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop and...
22:12 , Jun 4, 2018 |  BC Extra  |  Company News

CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
17:47 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Blueprint reports Phase I data for avapritinib in systemic mastocytosis

Blueprint Medicines Corp. (NASDAQ:BPMC) reported its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of 72% in 18 evaluable patients with advanced systemic mastocytosis (SM) in a Phase I trial. Data...
17:14 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Blueprint prices $345M follow-on

Blueprint Medicines Corp. (NASDAQ:BPMC) raised $345 million through the sale of 4.3 million shares at $81 in a bumped-up follow-on underwritten by Goldman Sachs, Morgan Stanley, Cowen and Canaccord Genuity. The figure includes the sale...
18:55 , Dec 13, 2017 |  BC Extra  |  Financial News

Blueprint raises $300M follow-on

Blueprint Medicines Corp. (NASDAQ:BPMC) raised $300 million late Tuesday through the sale of 3.7 million shares at $81 in a bumped-up follow-on underwritten by Goldman Sachs, Morgan Stanley, Cowen and Canaccord Genuity. The price is...
23:14 , Dec 11, 2017 |  BC Extra  |  Clinical News

Blueprint proposes $275M follow-on after ASH gains

Blueprint Medicines Corp. (NASDAQ:BPMC) gained $16.46 (23%) to $88.32 on Monday after reporting its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of 72% in 18 evaluable patients with advanced systemic...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
20:44 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Blueprint reports updated Phase I data for BLU-285 in GIST

Blueprint Medicines Corp. (NASDAQ:BPMC) reported updated data from an open-label, international Phase I trial evaluating once-daily 30-600 mg oral BLU-285 to treat unresectable gastrointestinal tumors (GIST) and other relapsed or refractory solid tumors. In 25...
17:14 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Blueprint reports additional Phase I data for BLU-285 in GIST

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Blueprint Medicines Corp. (NASDAQ:BPMC) reported additional data from an open-label, international Phase I trial evaluating once-daily 30-600 mg oral BLU-285...
22:56 , Dec 14, 2016 |  BC Week In Review  |  Clinical News

BLU-285: Preliminary Ph I data

Preliminary data from 12 patients with advanced systemic mastocytosis in the dose-escalation portion of an open-label, U.S. and U.K. Phase I trial showed that once-daily doses of 30, 60 and 100 mg oral BLU-285 were...